Invitation to Roche's Virtual Pipeline Event: Phase 2 LADDER results of the Port Delivery System (PDS) with Lucentis to be presented at the 2018 ASRS annual meeting
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Thursday, 2 August 2018, featuring data from the Phase 2 LADDER study of the Port Delivery System (RPDS) with Lucentis to be presented at the American Society of Retina Specialists (ASRS) annual meeting (20-25 July 2018) in Vancouver, Canada. (Source: Roche Investor Update)
Source: Roche Investor Update - July 11, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Lucentis (ranibizumab injection) 0.3 mg prefilled syringe for diabetic macular edema and diabetic retinopathy
Roche today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis ® (ranibizumab injection) 0.3 mg prefilled syringe (PFS) as a new method of administering the medicine to treat all forms of diabetic retinopathy. (Source: Roche Investor Update)
Source: Roche Investor Update - March 22, 2018 Category: Pharmaceuticals Source Type: news

Genentech ’ s pre-filled syringe for diabetic retinopathy wins FDA nod
Roche‘s (OTC:RHHBY) Genentech announced today that the FDA approved its 0.3-mg pre-filled syringe as a new way to administer Lucentis to diabetic retinopathy patients. The company’s drug is the only FDA-approved medicine indicated for the treatment of diabetic retinopathy. The 0.3-mg pre-filled syringe is the first device of its kind approved to deliver an anti-vascular endothelial growth factor agent to patients with diabetic retinopathy and diabetic macular edema. Get the full story at our sister site, Drug Delivery Business News. The post Genentech’s pre-filled syringe for diabetic retinopath...
Source: Mass Device - March 21, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat Genentech Roche Source Type: news

FDA Approves Genentech ’s Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy
South San Francisco, CA -- March 21, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis (ranibizumab injection) 0.3 mg prefilled syringe... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 21, 2018 Category: Drugs & Pharmacology Source Type: news

893716 893716
Biomarkers from the anterior chamber of the eye help predict response to ranibizumab, which could spare patients repeated injections with an ineffective agent, a small trial suggested.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 9, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Biomarkers May Predict Rx Response in Diabetic Macular Edema Biomarkers May Predict Rx Response in Diabetic Macular Edema
Biomarkers from the anterior chamber of the eye help predict response to ranibizumab, which could spare patients repeated injections with an ineffective agent, a small trial suggested.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 9, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Repeated Ranibizumab Injections Safe in Diabetic Macular Edema Repeated Ranibizumab Injections Safe in Diabetic Macular Edema
In patients with diabetic macular edema, repeated ranibizumab injections are not associated with impaired macular perfusion and can be safely offered even to those with severe microangiopathy and advanced capillary dropout, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 8, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Ranibizumab Safe, Effective for Macular Edema Due to Uncommon Causes Ranibizumab Safe, Effective for Macular Edema Due to Uncommon Causes
Ranibizumab 0.5 mg is safe and effective for patients with macular edema (ME) that is not due to diabetes, retinal vein occlusion (RVO) or neovascular age-related macular degeneration (nAMD), according to findings from the PROMETHEUS randomized trial.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 28, 2018 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Anti-VEGF Agents Improve Vision Despite Ongoing Diabetic Macular Edema Anti-VEGF Agents Improve Vision Despite Ongoing Diabetic Macular Edema
In patients with diabetic macular edema (DME), aflibercept and ranibizumab are more effective than bevacizumab in preventing disease persistence, but each drug can lead to substantial gains in vision, according to a post hoc analysis of a randomized trial.Reuters Health Information (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 14, 2018 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Low-dose Ranibizumab Effective for Retinopathy of Prematurity Low-dose Ranibizumab Effective for Retinopathy of Prematurity
Low doses of anti-VEGF therapy with ranibizumab are effective in infants with retinopathy of prematurity (ROP), according to results from the CARE-ROP study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 9, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Ohr Pharmaceutical shares plummet after eye drug fails in wet-AMD trial
Shares in Ohr Pharmaceutical (NSDQ:OHRP) dropped -83% to trade at 35¢ apiece this morning after the company revealed that its topical therapy did not meet the primary endpoint of a trial evaluating its efficacy as a treatment for wet age-related macular degeneration. The company’s Mako study randomized patients 1:1 to receive either Ohr’s topical, twice-daily squalamine therapy in combination with monthly Lucentis injections or a placebo combined with Lucentis. Get the full story at our sister site, Drug Delivery Business News. The post Ohr Pharmaceutical shares plummet after eye drug fails in we...
Source: Mass Device - January 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Optical/Ophthalmic Pharmaceuticals Wall Street Beat ohrpharmaceutical Source Type: news

Dexamethasone Does Not Improve Vision in Persistent Diabetic Macular Edema Dexamethasone Does Not Improve Vision in Persistent Diabetic Macular Edema
Adding dexamethasone to continued ranibizumab treatment reduces retinal thickness but does not improve vision in patients with persistent diabetic macular edema (DME), according to results from a phase 2 randomized trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 20, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Taxpayers pay twice for crucial drugs like Avastin | Letters
Big pharma companies are charging over the odds for medicines developed with public funding, writeHeidi Chow andTabitha HaIt is shocking, but not surprising, that big drugs companies are threatening to sue the NHS for using cheaper versions of drugs that could save people from going blind (Drug firms trying to stop cheap eye treatment on NHS, 1 November). Another part of this story is that the two medicines in question – Lucentis (known generically as ranibizumab) and Avastin (bevacizumab) are based on the groundbreaking discovery of monoclonal antibodies, whichwere developed with UK public funding.The NHS itself fun...
Source: Guardian Unlimited Science - November 5, 2017 Category: Science Authors: Letters Tags: NHS Drugs Medical research Science Health Society Pharmaceuticals industry Business Blindness and visual impairment Disability Source Type: news

Policy and regulation stand in the way of NHS use of unlicensed eye injection drug with potential to save millions of pounds
Eye injection drugs recommended by NICE cost the NHS up to £ 447 million annually, but could be replaced by an unlicensed drug, bevacizumab, costing as much as ten times less. Use of the two licensed drugs, ranibizumab and aflibercept, has increased three-fold over the last five years, with some parts of England treating five times as many patients as others. (Source: University of Bristol news)
Source: University of Bristol news - November 1, 2017 Category: Universities & Medical Training Tags: Health, Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School, Faculty of Health Sciences, Population Health Sciences; Press Release Source Type: news

Ranibizumab Beats Laser for Diabetic Retinopathy Ranibizumab Beats Laser for Diabetic Retinopathy
New trial findings are challenging the standard of care for diabetic retinopathy and are opening the door to wider use of anti-vascular endothelial growth factor drugs.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 10, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Analysis Favors Aflibercept for Diabetic Macular Edema Analysis Favors Aflibercept for Diabetic Macular Edema
Aflibercept appears to be more effective than ranibizumab, with or without laser photocoagulation, in a new meta-analysis of treatments for diabetic macular edema.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 9, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Opthea touts data from wet-AMD trial
Opthea (ASX:OPT) touted additional data today from the Phase I/IIa trial of its wet age-related macular degeneration therapy, OPT-302. The 50-patient Phase I/IIa trial recruited participants who were either treatment-naive or previously treated with an intravitreal anti-VEGF therapy. Researchers evaluated OPT-302 as a monotherapy and in combination with Lucentis (ranibizumab). Get the full story at our sister site, Drug Delivery Business News. The post Opthea touts data from wet-AMD trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 15, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Opthea Source Type: news

Aflibercept May Be Effective for Resistant Exudative AMD Aflibercept May Be Effective for Resistant Exudative AMD
Aflibercept appears to improve outcomes in patients with exudative age-related macular degeneration (AMD) resistant to treatment with ranibizumab or bevacizumab, researchers from Norway report.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 14, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Minimal Differences Between Anti-VEGF Drugs on IOP Over Time Minimal Differences Between Anti-VEGF Drugs on IOP Over Time
Patients on anti-VEGF therapy may have a small decrease in intraocular pressure (IOP) over time, but with minimal differences between aflibercept, ranibizumab, and bevacizumab, a new large study suggests.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 1, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

FDA approves Roche ’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States
Roche today announced that the US Food and Drug Administration (FDA) approved Lucentis ® (ranibizumab injection) 0.3 mg for the monthly treatment of withal forms of diabetic retinopathy. (Source: Roche Media News)
Source: Roche Media News - April 18, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States
Roche today announced that the US Food and Drug Administration (FDA) approved Lucentis ® (ranibizumab injection) 0.3 mg for the monthly treatment of withal forms of diabetic retinopathy. (Source: Roche Investor Update)
Source: Roche Investor Update - April 18, 2017 Category: Pharmaceuticals Source Type: news

FDA OKs Ranibizumab for All Forms of Diabetic Retinopathy FDA OKs Ranibizumab for All Forms of Diabetic Retinopathy
The VEFG inhibitor had been approved just for diabetic retinopathy accompanied by diabetic macular edema, in addition to other eye disorders.FDA Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 18, 2017 Category: Endocrinology Tags: Ophthalmology News Alert Source Type: news

FDA Approves Genentech ’s Lucentis (ranibizumab) for all Forms of Diabetic Retinopathy
South San Francisco, CA -- April 17, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Lucentis ® (ranibizumab injection) 0.3 mg for the monthly... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 17, 2017 Category: Drugs & Pharmacology Source Type: news

Cardiovascular Safety of Ranibizumab for Diabetic Macular Edema Still Unclear Cardiovascular Safety of Ranibizumab for Diabetic Macular Edema Still Unclear
Uncertainty lingers about the cardiovascular safety of intravitreal ranibizumab injections for diabetic macular edema, a pooled analysis of clinical trials shows.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 12, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Opthea gets positive feedback from European regulatory groups for wet-AMD injection
Opthea (ASX:OPT) said today that it received positive feedback from meetings with the U.K.’s Medicines and Healthcare Products Regulatory Agency and Sweden’s Medical Products Agency over its OPT-302 therapy for the treatment of wet age-related macular degeneration. The Australia-based company’s OPT-302 therapy consists of a soluble form of vascular endothelial growth factor receptor 3 that blocks the activity of 2 proteins that cause blood vessels to grow and leak. It is being evaluated in a phase 1/2 clinical trial in patients with wet AMD as a monotherapy and with ranibizumab, delivered as monthly intra...
Source: Mass Device - March 20, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Regulatory/Clearance Wall Street Beat Opthea Source Type: news

Researchers develop micropump for patients with glaucoma
Researchers from the University of Southern California’s Roski Eye Institute developed a micropump that can be implanted directly into the eye and deliver a predetermined dose of the diabetic macular edema drug ranibizumab. Current treatments for glaucoma are traditionally delivered using eye drops. But studies show that some patients stop taking their prescription glaucoma eye drops after 1 year, according to the team of researchers. Patients can be uncomfortable using the eye drops or they forget to consistently take their prescribed medication. Get the full story at our sister site, Drug Delivery Busines...
Source: Mass Device - March 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Research & Development Replenish Inc Source Type: news

Lucentis (Ranibizumab Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 27, 2017 Category: Drugs & Pharmacology Source Type: news

Baseline Characteristics and Outcomes of Ranibizumab for DME Baseline Characteristics and Outcomes of Ranibizumab for DME
Data from this study provides insight into the patient characteristics and visual outcomes among those treated with ranibizumab injections for DME.The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 13, 2017 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

FDA Clears Ranibizumab for Myopic Choroidal Neovascularization FDA Clears Ranibizumab for Myopic Choroidal Neovascularization
Ranibizumab becomes the first FDA-approved anti-vascular endothelial growth factor therapy for mCNV.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 6, 2017 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news

FDA approves Lucentis (ranibizumab injection) for myopic choroidal neovascularisation
Roche announced today that the US Food and Drug Administration (FDA) has approved Lucentis ® (ranibizumab injection) 0.5 mg for the treatment of patients with myopic choroidal neovascularisation (mCNV), a complication of severe near-sightedness that can lead to blindness. (Source: Roche Investor Update)
Source: Roche Investor Update - January 6, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Genentech ’s Lucentis (ranibizumab) for Myopic Choroidal Neovascularization
South San Francisco, CA -- January 5, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis ® (ranibizumab injection) 0.5 mg for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 5, 2017 Category: Drugs & Pharmacology Source Type: news

Novartis eye drug franchise hit by failed Fovista studies
ZURICH (Reuters) - Novartis's bid to bolster its eye drug portfolio suffered a setback on Monday when it announced combining Lucentis with Fovista in patients with neovascular age-related macular degeneration (nAMD) did not produce better outcomes than treatment with Lucentis alone. (Source: Reuters: Health)
Source: Reuters: Health - December 12, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Ranibizumab Effective for Pigment Epithelial Detachment Ranibizumab Effective for Pigment Epithelial Detachment
Low-dose ranibizumab is effective in treating pigment epithelial detachment in patients with neovascular age-related macular degeneration, a post hoc analysis of the HARBOR study suggests.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 30, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Predicting Anti-VEGF Response in Diabetic Macular Edema Predicting Anti-VEGF Response in Diabetic Macular Edema
Response after 12 weeks of ranibizumab therapy can predict long-term outcomes in diabetic macular edema, a post hoc analysis suggests.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Is Anti-VEGF Monotherapy Best for Diabetic Macular Edema? Is Anti-VEGF Monotherapy Best for Diabetic Macular Edema?
One of the predictors of visual improvement in patients with diabetic macular edema is ranibizumab monotherapy, an analysis of the RESTORE data shows, but not everyone agrees with the findings.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 10, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Laser vs Drugs for Diabetic Retinopathy: Mostly a Toss-Up (CME/CE)
(MedPage Today) -- But Lucentis favored for some outcomes in randomized trial (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - September 6, 2016 Category: Opthalmology Source Type: news

New Data on RTH258 Show Promise New Data on RTH258 Show Promise
A recent phase 1/2 trial shows that RTH258 is a promising alternative to ranibizumab for the treatment of neovascular age-related macular degeneration.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 24, 2016 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

New Batches of Ranibizumab Biosimilar Safe, Effective New Batches of Ranibizumab Biosimilar Safe, Effective
Razumab, an Indian biosimilar for ranibizumab, appears to have overcome the high incidence of inflammation with a new manufacturing process, report investigators.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 15, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Ranibizumab T & amp;E cost effective for wet AMD in UK
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2016 Category: Drugs & Pharmacology Source Type: news

Doc's Dilemma: Lucentis or Avastin?
(MedPage Today) -- A physician weighs the risks and benefits (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 28, 2016 Category: American Health Source Type: news

Eye drug safety: the impact of a Cochrane Review comparing two treatments for macular degeneration
For more than 20 years, Cochrane has produced systematic reviews of primary research in human health care and health policy. We are internationally recognized as the highest standard in evidence-based healthcare resources.The fourth video in the Cochrane Making a Difference series focuses on the Cochrane Review 'Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration', published in September 2014 from the Cochrane Eyes & Vision Group. The review found that the systemic safety of bevacizumab for macular degeneration appears to be similar to that of ranibizumab - an important co...
Source: Cochrane News and Events - July 1, 2016 Category: Information Technology Authors: nowens at cochrane.org Source Type: news

Aflibercept, ranibizumab are not cost effective in DME
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2016 Category: Drugs & Pharmacology Source Type: news

Industry Incentives May Drive Pricier Anti-VEGF Drug UseIndustry Incentives May Drive Pricier Anti-VEGF Drug Use
Ophthalmologists with the most and largest payments had highest rates of injection with aflibercept and ranibizumab. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 23, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Two Expensive Diabetic Macular Edema Drugs Not Cost-effectiveTwo Expensive Diabetic Macular Edema Drugs Not Cost-effective
Anti-VEGF medicines aflibercept and ranibizumab would have to drop in price by 69% and 80%, respectively, to be worth the societal cost compared with bevacizumab, a new study has found. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

High-priced drugs used to treat diabetic macular edema not cost-effective
The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept, used to treat vision loss from diabetic macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are not cost-effective for treatment of DME compared to bevacizumab unless their prices decrease substantially, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 9, 2016 Category: Science Source Type: news

Newer Drugs Helping Older People With Eye Disease
FRIDAY, May 20, 2016 -- New medications are boosting quality of life for many older people with age-related macular degeneration (AMD), a new study indicates. The drugs Avastin and Lucentis have significantly increased the number of people with AMD... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 20, 2016 Category: Journals (General) Source Type: news

Long-term benefits of age-related macular degeneration treatments
A 5-year follow-up study confirmed the long-term benefits of using the drugs Avastin and Lucentis to treat age-related macular degeneration. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - May 9, 2016 Category: Consumer Health News Source Type: news

Age-related macular degeneration before and after the era of anti-VEGF drugs
NIH-funded study of Avastin and Lucentis examines their effects at five years. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - May 3, 2016 Category: American Health Source Type: news

Many With Wet AMD Need Ranibizumab Retreatment Even After Year-Long PauseMany With Wet AMD Need Ranibizumab Retreatment Even After Year-Long Pause
Retreatment with ranibizumab is necessary for up to a third of neovascular age-related macular degeneration (AMD) patients who are treatment-free for one year, new research shows. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 27, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Delayed Visual Improvements in AMD Continue With Ranibizumab TreatmentDelayed Visual Improvements in AMD Continue With Ranibizumab Treatment
Visual improvements in patients with neovascular age-related macular degeneration (AMD) treated with ranibizumab continue after macular edema resolves, researchers report. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - March 30, 2016 Category: Opthalmology Tags: Ophthalmology News Source Type: news